US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Prescription Drugs: market research reports

RSS Feeds

Prescription Drugs market research reports and industry analysis

  2    4  5  6  7  8  9  10  
Central America Pharmaceuticals and Healthcare Report Q4 2014
9/17/2014 | published by: Business Monitor International
... spending and strong consumer demand still present strong revenue-generatingopportunities for multimodal pharmaceutical companies. Headline Expenditure Projections Pharmaceuticals: USD3.5bn in 2013 to USD3.7bn in 2014; +4.1%. Our forecast has been revisedslightly down since Q314 due to ...  |  read more...
USD 1,295
Iran Pharmaceuticals and Healthcare Report Q4 2014
9/17/2014 | published by: Business Monitor International
... the rial means thatwe expect the value of the market to contract sharply in US dollar terms. While improved internationalrelations have reduced the regulatory risk associated with operating in the market for multinationaldrugmakers, the recent ...  |  read more...
USD 1,295
Kazakhstan Pharmaceuticals and Healthcare Report Q4 2014
9/17/2014 | published by: Business Monitor International
... country. However,the government continues to show its commitment to improving healthcare as it allocates more funds toconstructing new health clinics across the country. Although Kazakhstan's growing pharmaceuticalindustry will be driven by demand for generic medicines ...  |  read more...
USD 1,295
Slovenia Pharmaceuticals and Healthcare Report Q4 2014
9/17/2014 | published by: Business Monitor International
... We havetherefore downwardly revised our pharmaceutical forecast for 2014. A high budget deficit limits room forthe new government to increase funding for health services, and we expect healthcare spending to declinethis year and next, before ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Argentina Q4 2014
8/27/2014 | published by: Business Monitor International
... erode the growth ofthe country's pharmaceutical market. More foreign pharmaceutical companies will cease their localoperations, if the hostile business environment is worsened. Headline Expenditure Projections Pharmaceuticals: ARS39.30bn (USD7.18 bn) in 2013 to ARS50.10bn (USD6.04bn) in ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Colombia Q4 2014
8/27/2014 | published by: Business Monitor International
... bioequivalence regulationswill also undermine sale growth posted by branded generic drugmakers. However, Colombia's relativelyadvanced drug reimbursement system will still offer revenue-generating opportunities for multinationals incomparison with other second-tier Latin American pharmaceutical markets. Headline Expenditure Projections ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Mozambique Q4 2014
8/27/2014 | published by: Business Monitor International
... medicines and healthcare facilities. Vaccination programs and trials are being put into place, particularly for malaria and HIV immunisation,to help combat the county's high burden of disease. However, Mozambique's pharmaceutical market suffersfrom an abundance of ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Netherlands Q4 2014
8/27/2014 | published by: Business Monitor International
... austerity measures to meet the terms of EUbudget criteria and further restrictions on drug expenditure look likely, particularly on essential medicines. Although healthcare expenditure continues to increase (in local currency terms), we maintain our view ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Uganda Q4 2014
8/27/2014 | published by: Business Monitor International
... healthcare coverage which results in mostUgandans being unable to afford medicines, is placing a high level of strain on the country's ability toprovide adequate healthcare. Uganda also faces the threat of an Ebola outbreak spreading ...  |  read more...
USD 1,295
Cameroon Pharmaceuticals and Healthcare - Report Q4 2014
9/3/2014 | published by: Business Monitor International
... sectorimprovement in Cameroon over the medium term. These include mobile health technologies implementationin the fields of cardiology, HIV testing and personalised medical information across the country, as well ashospitals construction, foreign aid projects and different ...  |  read more...
USD 1,295
Nigeria Pharmaceuticals and Healthcare - Report Q4 2014
9/3/2014 | published by: Business Monitor International
... downside risk to increasinggovernment revenue, healthcare provision and medicines uptake over the long term. Currently, thegovernment remains committed to improving healthcare infrastructure and quality across the country. Wesee Nigeria as a standout market in West ...  |  read more...
USD 1,295
Turkey Pharmaceuticals and Healthcare - Report Q4 2014
9/3/2014 | published by: Business Monitor International
... higher yo-y growth rates return from 2013/14. In contrast to European markets where manufacturers can expect toachieve higher prices, but with a stagnant growth outlook, Turkey offers strong growth potential ifdrugmakers are able to accept ...  |  read more...
USD 1,295
Romania Pharmaceutical Report - Q2, 2014
9/4/2014 | published by: Intellinews
... to RON 3bn (EUR 679.8mn) in Q2/2014, returning to growth after having declined on an annual basis for three consecutive quarters. In volume terms, the market also rose by 3.2% y/y in Q2, recovering from ...  |  read more...
USD 475
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Australia
9/1/2014 | published by: GlobalData
... information on and analysis of the healthcare, regulatory and reimbursement landscape in Australia. It identifies the key trends in the country‚Äôs healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare ...  |  read more...
USD 1,995
Brazil Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... aresignificant revenue-generating opportunities for drugmakers, medical device companies and healthcareservice providers. However, multinationals will continue to face increasing government intervention anddomestic competition. Headline Expenditure Projections Pharmaceuticals: BRL57.0bn (USD26.4bn) in 2013 to BRL62.0bn (USD26.6bn) in 2014; ...  |  read more...
USD 1,295
Canada Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... regulatory authority also encourages pharmaceutical companies to invest in research anddevelopment. However, cost containment policies in the public healthcare sector will continue to putpressure on Canada's medicine prices. Headline Expenditure Projections Pharmaceuticals: CAD25.6bn (USD24.9bn) in ...  |  read more...
USD 1,295
Bahrain Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... to only moderategrowth in the short term. Longer term, the country's ageing population, increasing chronic diseases burdenand robust economic growth will drive medicine demand; however, further medicine price cuts, lower-thanexpectedoil prices in coming years and ...  |  read more...
USD 1,295
Belgium Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... per capita spending onpharmaceuticals is relatively high, it is subjected to continual downward pressure from Eastern Europe andAsia, which translates into growth opportunities for generic drugs. However, prescribers' brand loyalty,pay-to-delay deals, the near-universal unpopularity of ...  |  read more...
USD 1,295
Germany Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... putting furtherpressure on drugmakers looking to benefit from marketing their products in other European markets. Despite this situation, Germany will remain an attractive market to drugmakers. The long-term and clearnature of the price measures implemented ...  |  read more...
USD 1,295
Hungary Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... risk team also sees potential headwindsto spending growth, namely Hungary's excessive government deficits. Under Deficit Procedure rules,Hungary will be forced to trim back its fiscal spending, with negative implications for healthcare. Pricingpressures and slow uptake ...  |  read more...
USD 1,295
Jordan Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... stillprevalent in the market, although steps are being taken to combat this, such as the Jordan Food and DrugAdministration (JFDA)'s recent conference. Although we forecast growth for both the pharmaceutical andhealthcare sectors, our outlook is ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Angola Q4 2014
8/27/2014 | published by: Business Monitor International
... attracting external revenues. Angola'shigh burden of communicable disease, such as measles and malaria, will mean that the demand forvaccines remain high. However, the country's pharmaceutical and healthcare market is greatly affected byits difficult operating environment, ...  |  read more...
USD 1,295
Romania Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... in theconsumer outlook and the country's macroeconomic prospects, in line with the views of our Country Riskteam. Provided unemployment continues to pare down and economic growth continues, the pharmaceuticalmarket will continue on its current growth ...  |  read more...
USD 1,295
Cote d'Ivoire Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... lack of policy enforcement and approvalsexpediency and a generally weak business setting. The healthcare market remains underdeveloped, whilethe burden of communicable diseases is considerable. Nevertheless, we have a more positive outlook foreconomic and pharmaceutical growth ...  |  read more...
USD 1,295
Taiwan Pharmaceuticals and Healthcare Report - Q4 2014
9/10/2014 | published by: Business Monitor International
... Given theincreasing demand for health services from the ageing population, Taiwan will continue to limit theescalation of drug prices, which will negatively impact the pharmaceutical market's growth potential. Inparticular demand for long-term care and welfare ...  |  read more...
USD 1,295
  2    4  5  6  7  8  9  10